Epigenetic Mechanisms in Alzheimer's Disease

Epigenetic Mechanisms in Alzheimer's Disease

Introduction

Overview

Epigenetic mechanisms — heritable changes in gene expression without alterations to the underlying DNA sequence — have emerged as critical players in Alzheimer's Disease (AD) pathogenesis. These mechanisms include DNA methylation, histone modifications, chromatin remodeling, non-coding RNA regulation, and RNA modifications. The dynamic and potentially reversible nature of epigenetic modifications makes them attractive therapeutic targets, unlike fixed genetic mutations [@graff].

AD exhibits global epigenetic alterations, with evidence of both hypermethylation and hypomethylation at different genomic loci. The complex pattern of epigenetic dysregulation
reflects the interaction between genetic susceptibility (particularly APOE become hypomethylated and transcriptionally reactivated in AD, contributing to genomic instability,
double-strand DNA breaks, and activation of the cGAS-STING] innate immune pathway through cytosolic DNA accumulation [@guo2018].

DNA Methylation in Alzheimer's Disease

DNA methylation — the addition of methyl groups to cytosine residues in CpG dinucleotides — is the most studied epigenetic modification in AD. Genome-wide studies have identified widespread DNA methylation changes in AD brain and blood tissue [@lunnon2014; @stathatos; @chang]. These changes occur at multiple loci, including genes involved in neuronal function, immune response, and cellular metabolism.

Differential Methylation in AD Brain

Epigenetic Mechanisms in Alzheimer's Disease

Introduction

Overview

Epigenetic mechanisms — heritable changes in gene expression without alterations to the underlying DNA sequence — have emerged as critical players in Alzheimer's Disease (AD) pathogenesis. These mechanisms include DNA methylation, histone modifications, chromatin remodeling, non-coding RNA regulation, and RNA modifications. The dynamic and potentially reversible nature of epigenetic modifications makes them attractive therapeutic targets, unlike fixed genetic mutations [@graff].

AD exhibits global epigenetic alterations, with evidence of both hypermethylation and hypomethylation at different genomic loci. The complex pattern of epigenetic dysregulation
reflects the interaction between genetic susceptibility (particularly APOE become hypomethylated and transcriptionally reactivated in AD, contributing to genomic instability,
double-strand DNA breaks, and activation of the cGAS-STING] innate immune pathway through cytosolic DNA accumulation [@guo2018].

DNA Methylation in Alzheimer's Disease

DNA methylation — the addition of methyl groups to cytosine residues in CpG dinucleotides — is the most studied epigenetic modification in AD. Genome-wide studies have identified widespread DNA methylation changes in AD brain and blood tissue [@lunnon2014; @stathatos; @chang]. These changes occur at multiple loci, including genes involved in neuronal function, immune response, and cellular metabolism.

Differential Methylation in AD Brain

The landmark 2014 study by De Jager et al. was the first to perform epigenome-wide association analysis (EWAS) in AD brain cortex, identifying differentially methylated positions (DMPs) at multiple loci including ANK1, BIN1, RHBDF2, and ABCA1 [@de]. Subsequent studies confirmed these findings and expanded the list of altered loci across multiple brain regions [@smith; @hernandez]. ANK1 (ankyrin repeat domain 1) shows some of the most consistent hypermethylation in AD, particularly in the hippocampus and entorhinal cortex — regions most vulnerable to neurodegeneration.

Blood-Based DNA Methylation Biomarkers

Several studies have identified DNA methylation signatures in blood that correlate with AD pathology and can serve as accessible biomarkers.Hernandez et al. demonstrated distinct blood DNA methylation patterns in AD patients compared to controls, with some overlap with brain changes [@hernandez]. Lord et al. showed that epigenetic age acceleration — where DNA methylation-based age exceeds chronological age — is associated with increased AD risk and faster cognitive decline [@lord]. This finding suggests that accelerated biological aging, as measured by epigenetic clocks, may be a modifiable risk factor for AD.

Tau-Mediated Epigenetic Changes

Tau pathology itself can drive epigenetic alterations. Guo et al. demonstrated that tau induces genome-wide promoter DNA methylation changes in AD, providing a mechanistic link between tau pathology and transcriptional dysregulation [@guo2018]. These findings were extended by Song et al. who explored the specific role of DNA methylation in tauopathies and AD progression [@song].

Histone Modifications in Alzheimer's Disease

Histone modifications alter chromatin structure through acetylation, methylation, phosphorylation, ubiquitination, SUMOylation, and other post-translational modifications. These changes regulate gene expression by modifying histone-DNA interactions or recruiting chromatin-binding effector proteins [@graffa].

Histone Acetylation

Histone acetylation, mediated by histone acetyltransferases (HATs: CBP/p300, GCN5, Tip60), neutralizes the positive charge of lysine residues, relaxing chromatin and promoting transcription. HDAC enzymes remove acetyl groups, generally promoting chromatin compaction and transcriptional repression. In AD, altered HDAC/HAT balance contributes to transcriptional dysregulation and cognitive deficits.

Rao et al. demonstrated significantly increased acetylation of histone H3 in AD brain tissue, particularly in the hippocampus [@rao]. This altered acetylation pattern correlates with changes in gene expression related to synaptic plasticity and neuronal function. Karat et al. further confirmed global changes in both histone acetylation and methylation in AD brains [@karat].

HDAC2 is significantly overexpressed in AD brains, particularly in hippocampus and entorhinal cortex — regions vulnerable to early pathology [@grff]. HDAC2 binds to promoters of synaptic plasticity genes (including those encoding AMPA and NMDA receptor receptor subunits, BDNF, and CaMKII), repressing their transcription and contributing to memory impairment. Aβ oligomers induce HDAC2 upregulation through a glucocorticoid receptor-mediated pathway.

Marathe et al. documented altered HDAC expression in temporal cortex and hippocampus in AD, with specific changes in HDAC2 and other Class I HDACs [@marathe]. Wen et al. reviewed the therapeutic potential of HDAC inhibitors in AD, highlighting both the promise and challenges of this approach [@wen].

H4K16 acetylation (H4K16ac) is globally reduced in AD brain tissue. H4K16ac is a key mark for maintaining euchromatin and preventing heterochromatin spreading. Its loss leads to silencing of neuronal genes and reactivation of normally repressed genomic regions.

Sun et al. demonstrated specific epigenetic regulation of histone modifications and glutaminase 1 expression in AD brain, linking epigenetic changes to metabolic alterations [@sun]. Goodman et al. showed that HDAC inhibitor effects on memory require BDNF expression, providing a mechanistic link between histone acetylation and neuronal function [@goodman].

Pharmacological HDAC inhibition reverses cognitive deficits in mouse models of AD, restoring expression of synaptic plasticity genes and improving memory performance. Saab et al. demonstrated that histone modifications and specific histone deacetylases are required for memory formation [@saab]. However, broad-spectrum HDAC inhibitors (such as SAHA/vorinostat, valproic acid, and sodium butyrate) cause undesirable side effects including immunosuppression and cardiac toxicity, driving interest in isoform-selective inhibitors targeting HDAC2 or HDAC6 specifically.

Histone Methylation

Histone methylation can activate or repress transcription depending on the modified residue and degree of methylation:

• H3K4me3 (activating): Altered at genes involved in neuronal survival and synaptic function. Loss of H3K4me3 at BDNF and Arc promoters correlates with reduced expression and cognitive decline.
• H3K9me3 (repressive): Loss of repressive H3K9me3 marks leads to aberrant re-expression of developmental genes in AD neurons — a phenomenon termed "epigenetic derepression" that contributes to cell cycle re-entry, a recognized pathway to neuronal death [@frost].
• H3K27me3 (repressive, Polycomb-mediated): Shows complex redistributive patterns in AD, with loss at neuronal identity genes and gain at synaptic genes. EZH2, the methyltransferase responsible for H3K27me3, is dysregulated in AD.
• H3K36me2: Increased at inflammatory gene promoters in AD microglia shows altered expression and binding patterns in AD, affecting genes critical for neuronal function. BAF complex (a SWI/SNF variant) subunit composition shifts in AD neurons, reducing neuronal-specific nBAF complexes while increasing progenitor-associated npBAF complexes, potentially reflecting dedifferentiation.

CTCF (CCCTC-binding factor), the primary architectural protein defining TAD boundaries, shows reduced binding in AD hippocampus. Loss of CTCF boundary function leads to inappropriate enhancer-promoter contacts and aberrant gene activation, potentially contributing to the transcriptional chaos observed in advanced AD.

Non-Coding RNAs in Alzheimer's Disease

MicroRNAs

MicroRNAs (miRNAs) are small (20–22 nucleotide) non-coding RNAs that regulate gene expression by guiding the RNA-induced silencing complex (RISC) to complementary sequences in the 3'UTR of target mRNAs, leading to translational repression or mRNA degradation. Specific miRNA signatures distinguish AD from control brains and correlate with neuropathological changes [@lee].

Geigl et al. reviewed circulating miRNAs as biomarkers for AD, highlighting their potential for non-invasive diagnosis [@geigl]. Satoh et al. performed microarray analysis identifying specific miRNA expression profiles in AD brains [@satoh]. Kumar et al. demonstrated that circulating miRNA signatures in blood can reflect brain pathology in AD, providing a link between peripheral biomarkers and central nervous system changes [@kumar].

Key AD-associated miRNAs:

• miR-132: The most consistently downregulated miRNA in AD brain. miR-132 targets tau kinase GSK3β, the splicing factor PTBP2, and FOXO3a. Its loss leads to increased tau phosphorylation, altered tau splicing (favoring 4R tau), and impaired autophagy. miR-132 supplementation reverses tau pathology in mouse models.
• miR-146a: Upregulated in AD brain and CSF. Targets complement factor H (CFH) and TRAF6, promoting neuroinflammation and complement-mediated synaptic loss.
• miR-125b: Overexpressed in AD, promotes tau hyperphosphorylation by targeting DUSP6 and PPP1CA phosphatases.
• miR-29a/b-1: Downregulated in AD and directly targets BACE1.

Long Non-Coding RNAs and Circular RNAs

Beyond miRNAs, other non-coding RNAs are implicated in AD. Leggio et al. explored lncRNAs and circular RNAs as potential biomarkers in AD [@leggio]. van den Boom et al. specifically investigated circular RNAs as novel biomarkers in AD [@van_den_boom]. Zhou et al. reviewed the role of lncRNAs in synaptic dysfunction in AD [@zhou].

N6-Methyladenosine (m6A)

N6-methyladenosine (m6A) is the most abundant internal modification on eukaryotic mRNA, regulating mRNA splicing, export, translation, and stability. m6A is installed by "writers" (METTL3/METTL14/WTAP complex), removed by "erasers" (FTO, ALKBH5), and interpreted by "readers" (YTHDF1/2/3, YTHDC1/2) [@han].

In the normal brain, m6A sites increase with age, predominantly within the 3'UTR of transcripts encoding synaptic proteins. However, this age-dependent m6A increase is disrupted in AD. METTL3, the catalytic m6A methyltransferase, shows significantly reduced expression in AD hippocampus neurons. METTL3 knockdown in mice causes memory deficits, synaptic loss, and neuronal death, demonstrating a causal role [@zhao].

A 2025 study revealed that m6A modification of promoter-antisense RNAs (paRNAs) is profoundly rewired in AD brains, affecting 3D chromatin organization and neuronal gene regulation. This connects epitranscriptomic changes directly to chromatin architecture disruption in AD [@deng].

m6A also regulates the expression of tau: m6A modification of MAPT mRNA influences its stability and translation. Changes in m6A at specific MAPT mRNA positions may contribute to the altered tau isoform ratios observed in AD. The m6A reader YTHDF2, which promotes mRNA degradation, is reduced in AD, potentially contributing to the increased stability of pathogenic transcripts.

Other RNA Modifications

Beyond m6A, other RNA modifications are emerging as relevant to AD:

• 5-methylcytosine (m5C) on tRNA and mRNA: Regulated by NSUN2; loss of NSUN2 causes neurodegeneration in animal models.
• Pseudouridine (Ψ): The most common RNA modification; changes in pseudouridylation of rRNA may impair translation fidelity in AD neurons.
• A-to-I RNA editing by ADAR enzymes: Editing of glutamate receptor (GluA2) mRNA is critical for neuronal survival; altered editing patterns are reported in AD.

Epigenetic Clocks and Biological Age

DNA methylation-based epigenetic clocks (Horvath clock, Hannum clock, GrimAge, DunedinPACE) provide estimates of biological age that predict mortality and morbidity better than chronological age. Epigenetic age acceleration — when biological age exceeds chronological age — is consistently associated with increased AD risk and faster cognitive decline [@levine].

The GrimAge clock, which incorporates methylation surrogates for plasma proteins and smoking pack-years, shows the strongest associations with AD neuropathology and incident dementia. DunedinPACE, measuring the pace of biological aging, demonstrates that faster aging rates predict amyloid accumulation and hippocampal atrophy in cognitively normal individuals. These findings suggest that interventions slowing biological aging (as measured by epigenetic clocks) could reduce AD risk.

Brain-specific epigenetic clocks reveal that the AD cortex is biologically older than expected, with the degree of epigenetic age acceleration correlating with Braak staging and cognitive impairment. Clinical trials of SAM or B-vitamin supplementation for AD prevention have yielded mixed results, possibly due to intervention timing.

Exercise and Epigenetic Reprogramming

Physical exercise improves cognitive function and reduces AD risk partly through epigenetic mechanisms. Exercise induces DNA hypomethylation at synaptic plasticity gene promoters (BDNF, ARC, HOMER1), increases histone H3 acetylation in the hippocampus, and elevates expression of HATs while reducing HDAC2 levels. Aerobic exercise also increases blood levels of the myokine irisin, which crosses the Blood-Brain Barrier and promotes BDNF expression through epigenetic derepression.

Early-Life Programming

The Developmental Origins of Health and Disease (DOHaD) hypothesis extends to AD. Maternal nutrition, stress, and environmental toxin exposure during pregnancy influence offspring brain development through epigenetic programming. Lead (Pb) exposure in early life causes persistent DNA methylation changes at AD-related genes (APP, BACE1 in offspring, with effects persisting into adulthood and increasing vulnerability to neurodegeneration.

Therapeutic Approaches

HDAC Inhibitors

Histone deacetylase inhibitors represent the most advanced epigenetic therapy for AD [@bhat; @wen]:

• Pan-HDAC inhibitors: Vorinostat (SAHA), sodium butyrate, and valproic acid improve cognition in AD mouse models but have dose-limiting toxicity in humans.
• HDAC2-selective inhibitors: BRD6688 and other HDAC2-selective compounds show improved safety profiles while maintaining efficacy in preclinical models. HDAC2 selectivity is challenging due to high structural similarity among Class I HDACs.
• HDAC6 inhibitors: Tubastatin A and ACY-1215 (ricolinostat) inhibit the cytoplasmic HDAC6, which deacetylates tau (promoting aggregation) and α-tubulin (impairing axonal transport). HDAC6 inhibition reduces tau pathology and restores axonal transport in AD models.

DNMT Modulators

DNA methyltransferase inhibitors (5-azacytidine, decitabine) are FDA-approved for myelodysplastic syndromes and could theoretically correct hypermethylation at AD-relevant loci. However, their lack of locus specificity and potential toxicity limit CNS application. Low-dose decitabine showed neuroprotective effects in AD mouse models by demethylating BDNF and synaptic gene promoters.

Epigenome Editing

CRISPR-based epigenome editing tools — dCas9 fused to DNMT3A (for targeted methylation), TET1 (for targeted demethylation), or p300 (for targeted acetylation) — enable precise modification of epigenetic marks at specific genomic loci without altering the DNA sequence. These technologies offer the potential to correct pathological epigenetic alterations with locus specificity that small molecules cannot achieve. AAV vectors carrying epigenome editors have been tested in preclinical models, with CRISPR-dCas9-TET1 successfully demethylating and reactivating silenced BDNF in AD mouse hippocampus [@liu]. Brain delivery and off-target editing remain key challenges.

miRNA-Based Therapeutics

Synthetic miR-132 mimics delivered via lipid nanoparticles or AAV vectors reduce tau pathology and improve cognition in AD mouse models. Anti-miRNA oligonucleotides targeting upregulated miRNAs (miR-146a, miR-125b) are in preclinical development. The success of nusinersen and other antisense oligonucleotide therapies for neurodegenerative diseases provides a translational framework for CNS-targeted RNA therapeutics.

Lifestyle Interventions

Non-pharmacological interventions including exercise, cognitive training, Mediterranean diet, and stress reduction (meditation, yoga) modify epigenetic marks relevant to AD. The FINGER trial demonstrated that a multidomain lifestyle intervention improved cognition in at-risk individuals, and sub-studies suggest epigenetic mechanisms contribute to these benefits. These approaches offer low-risk strategies for AD prevention, potentially working through cumulative epigenetic reprogramming.

Gene Therapy Approaches

Emerging genetic therapies offer additional pathways for AD treatment:

• Antisense Oligonucleotides (ASOs): IONIS-MAPT is an ASO targeting MAPT mRNA in Alzheimer's Disease, showing safety and biomarker effects in healthy volunteers.
• AAV Vectors: Clinical trials using AAV2-GAD for Parkinson's Disease and AAVrh.10 delivering AADC demonstrate the potential for gene therapy approaches in neurodegeneration.
• CRISPR/Cas9 Genome Editing: Base editing and prime editing offer potential for precise genetic correction, though delivery challenges remain significant for CNS applications.

Biomarker Potential

Epigenetic biomarkers offer several advantages for AD diagnosis and monitoring:

• Blood DNA methylation: Differentially methylated positions in blood (particularly at ANK1, HOXA3, BIN1) reflect brain methylation changes and correlate with AD diagnosis. Methylation arrays on blood DNA provide a cost-effective screening approach.
• miRNA panels: Multi-miRNA panels in CSF and blood demonstrate high diagnostic accuracy for AD and can distinguish AD from other dementias. Exosome-encapsulated miRNAs are stable in blood and may better reflect brain miRNA profiles.
• Epigenetic age acceleration: GrimAge and DunedinPACE acceleration predict incident AD and could identify individuals for prevention trials.
• Histone modification profiling: Circulating nucleosomes carrying specific histone marks (H3K9me3, H3K27ac) are detectable in blood and are under investigation as AD biomarkers.

Recent Research Updates (2024-2026)

Recent advances in epigenetics research have revealed new mechanisms in Alzheimer's disease:

• Peripheral immunity epigenetics: Epigenetic dysregulation in Alzheimer's disease affects peripheral immunity, with DNA methylation changes in immune cells correlating with disease progression[@dube].
• Genetics and epigenetics integration: Integrated genetic and epigenetic analyses provide a comprehensive understanding of AD pathogenesis, revealing novel risk genes and regulatory mechanisms[@han].
• Epigenetics in neurodegeneration: Epigenetic modifications including DNA methylation, histone acetylation, and non-coding RNAs play crucial roles in neurodegenerative disease progression[@zhao].

External Links

• [PubMed)](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature
• [Roadmap Epigenomics Project](https://egg2.wustl.edu/roadmap/web_portal/) — Reference epigenomes
• [ENCODE](https://www.encodeproject.org/) — Encyclopedia of DNA elements
• [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data

Background

The study of Epigenetic Mechanisms In Alzheimer's Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [BACE1
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• Amyloid-Beta Aggregation
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [neuroinflammation](/mechanisms/neuroinflammation)
• [Microglia](/cell-types/microglia)
• [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)
• Proteostasis Failure

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 56 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 67% |
| Mechanistic Completeness | 50% |

Overall Confidence: 50%

Epigenetic Mechanisms in AD

Histone Modifications

References

bhat, ‘Targeting epigenetics: a novel promise for Alzheimer’’s Disease treatment’ (2020)
bhatia, Epigenetic modulation of autophagy in Alzheimer’s disease (2022)
chang, Genome-wide CpG methylation profiles reveal quantitative views of Alzheimer’s disease progression (2014)
chen, Epigenetic regulation of neuroinflammation in Alzheimer’s Disease (2022)
coppieters, DNA methylation in Alzheimer’s Disease (2012)
de, ‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’ (2014)
deng, Rewired m6A of promoter antisense RNAs in Alzheimer’s Disease regulates neuronal genes in 3D nucleome (2024)
dube, An atlas of cortical circular RNA expression in Alzheimer’s Disease brains and its relationship to AD neuropathology (2021)
frost, Tau promotes neurodegeneration through global chromatin relaxation (2018)
geigl, Circulating miRNAs as biomarkers for Alzheimer disease (2017)
goodman, HDAC inhibitor effects on memory and behavior require BDNF expression (2020)
graff, An epigenetic blockade of cognitive functions in the neurodegenerating brain (2012)
graffa, Epigenetic regulation of synaptic plasticity and memory (2012)
grff, An epigenetic blockade of cognitive functions in the neurodegenerating brain (2012)
guo2018, Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements (2018)
han, Abnormality of m6A mRNA methylation is involved in Alzheimer’s Disease (2021)
hernandez, Distinct DNA methylation changes in Alzheimer’s disease brains and blood (2018)
huang, Circular RNAs as biomarkers in Alzheimer’s Disease (2021)
karat, Histone acetylation and DNA methylation in Alzheimer’s disease (2015)
kim, Chromatin remodeling in Alzheimer’s Disease brain (2021)
kumar, Circulating miRNA signature in blood reflects brain pathology in Alzheimer’s disease (2021)
lee, MicroRNA in Alzheimer’s Disease (2017)
leggio, LncRNAs and circular RNAs as potential biomarkers in Alzheimer’s disease (2020)
levine, An epigenetic biomarker of aging for lifespan and healthspan (2018)
li, DNA methylation signatures of Alzheimer’s Disease in blood (2022)
liu, CRISPR-based epigenome editing for therapeutic gene modulation (2022)
lord, DNA methylation age is accelerated in Alzheimer’s disease (2020)
lu, Epigenetic age acceleration predicts cognitive decline in Alzheimer’s Disease (2022)
lunnon, Methylomic profiling identifies novel DNA methylation changes in Alzheimer’s Disease (2014)
marathe, Histone deacetylase expression in temporal cortex and hippocampus in Alzheimer’s disease (2013)
nott, Brain cell type-specific enhancer-promoter interactome maps and disease-risk association (2022)
park, Non-coding RNA dysregulation in Alzheimer’s Disease (2022)
poulogiannis, Epigenetic therapy in Alzheimer’s disease (2021)
rao, Increased acetylation of histone H3 in Alzheimer’s disease brain (2012)
saab, Rad53 and histone modifications repress the gene required for memory (2018)
saharan, DNA methylation and histone modifications in Alzheimer’s Disease pathogenesis (2022)
satoh, Microarray analysis identifies specific miRNA expression profiles in Alzheimer’s disease brains (2016)
smith, A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex (2024)
song, The role of DNA methylation in tauopathies and Alzheimer’s disease (2023)
stathatos, Genome-wide blood DNA methylation profiles in subjects with Alzheimer’s disease and controls (2015)
sun, Epigenetic regulation of histone modifications and glutaminase 1 expression in Alzheimer’s disease (2018)
van_den_boom, Circular RNAs as novel biomarkers in Alzheimer’s disease (2021)
wang, Histone deacetylase inhibition as a therapeutic strategy in Alzheimer’s Disease (2019)
wen, Histone deacetylases inhibitors as therapeutic agents for Alzheimer’s disease (2020)
wu, Multi-omics integration reveals epigenetic landscape of Alzheimer’s Disease (2023)
xu, Targeting epigenetic modifications for Alzheimer’s Disease treatment (2022)
zhang, m6A RNA methylation in Alzheimer’s Disease and related dementias (2023)
zhao, METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s Disease through aberrant cell cycle events (2021)
zhou, lncRNAs and their role in synaptic dysfunction in Alzheimer’s disease (2022)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
• [Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: BRD4
• [TET2-Mediated Demethylation Rejuvenation Therapy](/hypothesis/h-d7121bcc) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TET2
• [Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration](/hypothesis/h-0e614ae4) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SIRT3
• [HDAC3-Selective Inhibition for Clock Reset](/hypothesis/h-a9571dbb) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: HDAC3
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Temporal TET2-Mediated Hydroxymethylation Cycling](/hypothesis/h-a90e2e89) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: TET2

Related Analyses:

• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Epigenetic Mechanisms in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: